nRichDX

nRichDX Company is an emerging leader in the liquid biopsy sample preparation market, providing 75 times more target material (ctDNA, CTCs, exosomes, etc.) than existing molecular testing sample preparation systems. The company's patented Revolution™ system is the first high-yield IVD liquid biopsy sample preparation platform, capable of handling sample volumes from 1ml to 50ml and offering a single solution for multiple specimen types and targets. nRichDX addresses one of the biggest challenges in precision medicine—up to 50% of liquid biopsy-based molecular diagnostic tests (NGS, PCR, microarrays, etc.) yield inaccurate results due to insufficient target material. The Revolution platform significantly enhances detection sensitivity, enabling high-confidence test results, facilitating early detection, monitoring, timely treatment, and optimal patient outcomes.